Market news

Elevance Health has climbed 42.6% over the past year, yet the broader valuation checks still lean toward the stock looking cheap rather than stretched at current levels. The 42.6% one-year return puts Elevance Health firmly in the group of recent outperformers, raising the question of how much value is already reflected in the price. Recent earnings strength and raised earnings expectations can support the case for higher earnings power over time, while margin pressure and membership...

Peru's $366,050 purchase expands his direct stake to 10,908 shares, now valued at $4.03 million following the stock's 22% one-year gain.

Boudreaux's stake now totals ~172,000 directly held shares worth $63.51 million, as Elevance maintains an $80 billion market cap and $5.0 billion in trailing net income.

Elevance Health Inc. (NYSE:ELV) reported strong Q2 results and raised full-year guidance. Analysts have adjusted price targets for ELV stock.

Bernstein SocGen Group lifted its Elevance Health price target to US$482 from US$424, putting fresh attention on how analysts are reassessing the stock. Many research firms are sounding more constructive, pointing to steadier medical cost trends, support from Healthcare Services earnings, and a calmer policy backdrop, while still highlighting Medicaid and specialty drug costs as key risks. Read on to see what is driving this evolving analyst narrative and how you can keep track of the moving...

Elevance Health: Q2 Earnings Snapshot

Health insurance provider Elevance Health (NYSE:ELV) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.1% year on year to $50.47 billion. Its non-GAAP profit of $7.45 per share was 20% above analysts’ consensus estimates.

Health insurance shares moved sharply lower in premarket trading after Elevance Health’s (NYSE:ELV) latest quarterly results revealed continued pressure on margins within its core Health Benefits business, raising concerns that similar challenges could affect the wider managed-care sector. Margin weakness overshadows earnings beatAlthough Elevance reported second-quarter earnings and revenue that comfortably exceeded analysts’ expectations, investors focused on the deterioration in profitability

Elevance Health reported second quarter net income of $1.45 billion as medical costs fell in some health plans, triggering an improved outlook for the rest of the year.

Elevance Health (ELV) delivered earnings and revenue surprises of +20.55% and +2.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CEO Boudreaux raised full-year guidance after beating Q2 projections.

The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Elevance Health (NYSE:ELV) reported stronger-than-expected second-quarter earnings and raised its full-year outlook, but the health insurer’s shares fell more than 9 percent in premarket trading as investors focused on declining profit margins. Earnings and revenue surpass expectationsThe company posted adjusted earnings per share of 7.

Elevance Health (NYSE:ELV) reported second quarter results that exceeded internal expectations. The company raised its full year guidance following the quarterly update. Management outlined plans to exit additional underperforming Medicaid markets. Elevance Health highlighted a focus on expanding Medicare Advantage and Carelon health services. Elevance Health is one of the largest U.S. managed care companies, with a broad footprint across commercial, Medicaid, Medicare Advantage, and health...

Detailed price information for Elevance Health Inc (ELV-N) from The Globe and Mail including charting and trades.

Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Equity and Income Fund”. A copy of the letter can be downloaded here. Oakmark Equity and Income Fund aims to maximize returns while preserving and enhancing capital. The portfolio consists of US equities and fixed-income securities. The allocation was 60.1% in equities, 38.9% […]

This week’s Elevance Health and UnitedHealth Group quarterly earnings are much anticipated for signs health insurers are keeping a handle on rising costs.

Health insurance provider Elevance Health (NYSE:ELV) will be reporting results this Wednesday before market hours. Here’s what to look for.

ELV faces Q2 pressure as weaker Health Benefits results and higher benefit expenses may weigh on earnings ahead of its July 15 report.

In late June 2026, Elevance Health, Inc. was removed from the Russell 1000 Value-Defensive and Russell 1000 Defensive indexes but added to the Russell 1000 Dynamic Index, while analysts projected a year-over-year earnings and revenue decline for the upcoming quarter. This combination of index reclassification and a weaker earnings outlook highlights how investors are reassessing Elevance Health’s risk profile and operational resilience within the health benefits space. With analysts...

Beyond analysts' top-and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ELV seeks to recover an estimated $115 million through a CMS lawsuit over Medicare Advantage Star Ratings and disputed bonus payments.

After a solid 22.7% 1 year return, Elevance Health is trading with valuation checks that still lean supportive. The question for investors is whether the recent share price strength has already captured most of the upside or not. Over the past year, Elevance Health has returned 22.7%, which puts recent gains front and center when judging how much value may be left on the table. On the fundamentals side, ongoing investments in platforms like Health OS can support earnings power, while...

Elevance Health (NYSE:ELV) has filed a lawsuit against the Centers for Medicare & Medicaid Services over how Medicare Advantage star ratings were recalculated. The company argues CMS used different processes for Elevance compared with Clover Health, which it says led to a substantial loss of bonus payments. The dispute centers on regulatory consistency and could influence how quality scores and related payments are handled for Medicare insurers. For investors tracking Elevance Health, the...